Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors

References

• Scanlan MJ, Raj B, Calvo B, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci. 1994;91:5657–5661.
   PubMed Web of Science ®Google Scholar
• Panevin TS, Zhelyabina OV, Eliseev MS, Shestakova MV. Urate-lowering effects of dipeptidyl peptidase-4 inhibitors. Diabetes mellitus. 2020;23:349–356. doi:10.14341/DM12412
   Web of Science ®Google Scholar
• De Meester I, Korom S, Van Damme J, Scharpé S. CD26, let it cut or cut it down. Immunol Today. 1999;20:367–375. doi:10.1016/S0167-5699(99)01486-3
   PubMedGoogle Scholar
• Thul PJ, Åkesson L, Wiking M, et al. A subcellular map of the human proteome. Science. 2017;356:eaal3321. doi:10.1126/science.aal3321
   PubMed Web of Science ®Google Scholar
• Busso N, Wagtmann N, Herling C, et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol. 2005;166:433–442. doi:10.1016/S0002-9440(10)62266-3
   PubMed Web of Science ®Google Scholar
• Klemann C, Wagner L, Stephan M, von Hörsten S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185:1–21. doi:10.1111/cei.12781
   PubMed Web of Science ®Google Scholar
• Vanderheyden M, Bartunek J, Goethals M, et al. Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Clin Chem Lab Med. 2009;47:248–252. doi:10.1515/CCLM.2009.065
   PubMed Web of Science ®Google Scholar
• Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495:251–254. doi:10.1038/nature12005
   PubMed Web of Science ®Google Scholar
• Wang N, Shi X, Jiang L, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013;23:986–993. doi:10.1038/cr.2013.92
   PubMed Web of Science ®Google Scholar
• Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;500:227–231. doi:10.1038/nature12328
   PubMed Web of Science ®Google Scholar
• Li K, Wohlford-Lenane C, Bartlett JA, McCray PB. Inter-individual variation in receptor expression influences MERS-CoV Infection and immune responses in airway epithelia. Front Public Health. 2021;2021:9.
   Google Scholar
• Huang J, Liu X, Wei Y, et al. Emerging role of dipeptidyl peptidase-4 in autoimmune disease. Front Immunol. 2022;2022:13.
   Google Scholar
• Cashin K, Gray LR, Jakobsen MR, Sterjovski J, Churchill MJ, Gorry PR. CoRSeq V3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm. Retrovirology. 2013;10:1–10. doi:10.1186/1742-4690-10-24
   PubMed Web of Science ®Google Scholar
• Wu L, Paxton WA, Kassam N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med. 1997;185:1681–1692. doi:10.1084/jem.185.9.1681
   PubMed Web of Science ®Google Scholar
• Rinkevich Y, Walmsley GG, Hu MS, et al. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential. Science. 2015;348:aaa2151. doi:10.1126/science.aaa2151
   PubMed Web of Science ®Google Scholar
• Oh M-D, Park WB, Choe PG, et al. Viral load kinetics of MERS coronavirus infection. N Engl J Med. 2016;375:1303–1305. doi:10.1056/NEJMc1511695
   PubMed Web of Science ®Google Scholar
• Abbott CA, McCaughan GW, Levy MT, Church WB, Gorrell MD. Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted β propeller domain. Eur J Biochem. 1999;266:798–810. doi:10.1046/j.1432-1327.1999.00902.x
   PubMedGoogle Scholar
• Yu D, Slaitini L, Gysbers V, et al. Soluble CD26/dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding. Scand J Immunol. 2011;73:102–111. doi:10.1111/j.1365-3083.2010.02488.x
   PubMed Web of Science ®Google Scholar
• Vankadari N, Wilce JA. Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerging Microbes Infect. 2020;9:601–604. doi:10.1080/22221751.2020.1739565
   PubMed Web of Science ®Google Scholar
• Sesti G, Avogaro A, Belcastro S, et al. Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetologica. 2019;56:605–617. doi:10.1007/s00592-018-1271-3
   PubMed Web of Science ®Google Scholar
• Tomovic K, Lazarevic J, Kocic G, Deljanin‐Ilic M, Anderluh M, Smelcerovic A. Mechanisms and pathways of anti‐inflammatory activity of DPP‐4 inhibitors in cardiovascular and renal protection. Med Res Rev. 2019;39:404–422. doi:10.1002/med.21513
   PubMed Web of Science ®Google Scholar
• Lu Z, Doulabi BZ, Wuisman P, Bank R, Helder M. Differentiation of adipose stem cells by nucleus pulposus cells: configuration effect. Biochem Biophys Res Commun. 2007;359:991–996. doi:10.1016/j.bbrc.2007.06.002
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol. 2019;389. doi:10.3389/fendo.2019.00389
   PubMed Web of Science ®Google Scholar
• Kushwaha R, Haq W, Katti S. Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective. Curr Med Chem. 2014;21:4013–4045. doi:10.2174/0929867321666140915143309
   PubMed Web of Science ®Google Scholar
• Li X, Huang X, Bai C, et al. Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2018;9:449. doi:10.3389/fphar.2018.00449
   PubMed Web of Science ®Google Scholar
• Panchapakesan U, Pollock C. The role of dipeptidyl peptidase–4 inhibitors in diabetic kidney disease. Front Immunol. 2015;6:443. doi:10.3389/fimmu.2015.00443
   PubMed Web of Science ®Google Scholar
• Panayi G, Lanchbury J, Kingsley G. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum. 1992;35:729–735. doi:10.1002/art.1780350702
   PubMed Web of Science ®Google Scholar
• Novikov A, Aleksandrova Е, Lukina G. Serum cytokine profile in early and established rheumatoid arthritis. Alman Clin Med. 2019;47:393–399. doi:10.18786/2072-0505-2019-47-058
   Google Scholar
• Sinnathurai P, Lau W, Vieira de Ribeiro AJ, et al. Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis. Internat J Rheum Dis. 2018;21:1915–1923. doi:10.1111/1756-185X.13031
   PubMed Web of Science ®Google Scholar
• Cordero OJ, Salgado FJ, Mera-Varela A, Nogueira M. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Internat. 2001;21:69–74. doi:10.1007/s002960100134
   PubMed Web of Science ®Google Scholar
• Grujic M, Matic IZ, Crnogorac MD, et al. Activity and expression of dipeptidyl peptidase IV on peripheral blood mononuclear cells in patients with early steroid and disease modifying antirheumatic drugs naïve rheumatoid arthritis. Clin Chem Laborat Med. 2017;55:73–81. doi:10.1515/cclm-2015-1279
   PubMed Web of Science ®Google Scholar
• Muscat C, Bertotto A, Agea E, et al. Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients. Clin Exp Immunol. 1994;98:252–256. doi:10.1111/j.1365-2249.1994.tb06134.x
   PubMed Web of Science ®Google Scholar
• Sromova L, Mareckova H, Sedova L, Balaziova E, Sedo A. Dipeptidyl peptidase-IV in synovial fluid and in synovial fluid mononuclear cells of patients with rheumatoid arthritis. Clin Chim Acta. 2010;411:1046–1050. doi:10.1016/j.cca.2010.03.034
   PubMed Web of Science ®Google Scholar
• Buljevic S, Detel D, Pucar LB, et al. Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients. Rheumatol Internat. 2013;33:2867–2874. doi:10.1007/s00296-013-2823-z
   PubMed Web of Science ®Google Scholar
• Kamori M, Hagihara M, Nagatsu T, Iwata H, Miura T. Activities of dipeptidyl peptidase II, dipeptidyl peptidase IV, prolyl endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis. Biochem Med Metab Biol. 1991;45:154–160. doi:10.1016/0885-4505(91)90016-E
   PubMedGoogle Scholar
• Cordero OJ, Varela-Calviño R, López-González T, et al. Anti-CD26 autoantibodies are involved in rheumatoid arthritis and show potential clinical interest. Clin. Biochem. 2017;50:903–910. doi:10.1016/j.clinbiochem.2017.06.001
   PubMed Web of Science ®Google Scholar
• Sedo A, Duke-Cohan JS, Balaziova E, Sedova LR. Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis? Arthritis Res Therapy. 2005;7:1–17. doi:10.1186/ar1852
   PubMed Web of Science ®Google Scholar
• Kanbe K, Chiba J, Inoue Y, Taguchi M, Yabuki A. SDF-1 and CXCR4 in synovium are associated with disease activity and bone and joint destruction in patients with rheumatoid arthritis treated with golimumab. Mod Rheumatol. 2016;26:46–50. doi:10.3109/14397595.2015.1054088
   PubMed Web of Science ®Google Scholar
• Sasaki T, Hiki Y, Nagumo S, et al. Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus. Diabetol Int. 2010;1:90–92. doi:10.1007/s13340-010-0010-y
   Google Scholar
• Glorie L, Behets GJ, Baerts L, De Meester I, d’Haese PC, Verhulst A. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats. Am J Physiol Endocrinol Metab. 2014;307:E447–E455. doi:10.1152/ajpendo.00217.2014
   PubMed Web of Science ®Google Scholar
• Yokota K, Igaki N. Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report. Internal Medicine. 2012;51:2041–2044. doi:10.2169/internalmedicine.51.7592
   PubMed Web of Science ®Google Scholar
• Padron S, Rogers E, Beckler MD, Kesselman M. DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis. BMJ Case Reports CP. 2019;12:e228981. doi:10.1136/bcr-2018-228981
   PubMedGoogle Scholar
• Mascolo A, Rafaniello C, Sportiello L, et al. Dipeptidyl peptidase (DPP)-4 inhibitor-induced arthritis/arthralgia: a review of clinical cases. Drug Safety. 2016;39:401–407. doi:10.1007/s40264-016-0399-8
   PubMed Web of Science ®Google Scholar
• Kathe N, Shah A, Said Q, Painter JT. DPP-4 inhibitor-induced rheumatoid arthritis among diabetics: a nested case–control study. Diabetes Therapy. 2018;9:141–151. doi:10.1007/s13300-017-0353-5
   PubMed Web of Science ®Google Scholar
• Douros A, Abrahami D, Yin H, et al. Use of dipeptidyl peptidase-4 inhibitors and new-onset rheumatoid arthritis in patients with type 2 diabetes. Epidemiology. 2018;29:904–912. doi:10.1097/EDE.0000000000000891
   PubMed Web of Science ®Google Scholar
• Charoenngam N, Rittiphairoj T, Ponvilawan B, Ungprasert P. Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of cohort studies. Diabetes Metab Syndr. 2021;15:249–255. doi:10.1016/j.dsx.2020.12.042
   PubMed Web of Science ®Google Scholar
• Bengsch B, Seigel B, Flecken T, Wolanski J, Blum HE, Thimme R. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol. 2012;188:5438–5447. doi:10.4049/jimmunol.1103801
   PubMed Web of Science ®Google Scholar
• Yamada Y, Jang J-H, De Meester I, et al. CD26 costimulatory blockade improves lung allograft rejection and is associated with enhanced interleukin-10 expression. J Heart Lung Transplant. 2016;35:508–517. doi:10.1016/j.healun.2015.11.002
   PubMed Web of Science ®Google Scholar
• Willheim M, Ebner C, Kern W, et al. Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T H1 subsets. J Allergy Clin Immunol. 1997;100:348–355. doi:10.1016/S0091-6749(97)70248-3
   PubMed Web of Science ®Google Scholar
• Lun SW, Wong C, Ko FW, Hui DS, Lam CW. Increased expression of plasma and CD4+ T lymphocyte costimulatory molecule CD26 in adult patients with allergic asthma. J Clin Immunol. 2007;27:430–437. doi:10.1007/s10875-007-9093-z
   PubMed Web of Science ®Google Scholar
• Salgado FJ, Pérez‐Díaz A, Villanueva NM, Lamas O, Arias P, Nogueira M. CD26: a negative selection marker for human Treg cells. Cytometry Part A. 2012;81:843–855. doi:10.1002/cyto.a.22117
   PubMedGoogle Scholar
• Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011;124:2338–2349. doi:10.1161/CIRCULATIONAHA.111.041418
   PubMed Web of Science ®Google Scholar
• Gliddon DR, Howard CJ. CD26 is expressed on a restricted subpopulation of dendritic cells in vivo. Europ J Immunol. 2002;32:1472–1481. doi:10.1002/1521-4141(200205)32:5<1472::AID-IMMU1472>3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Zhong J, Rao X, Deiuliis J, et al. A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation. Diabetes. 2013;62:149–157. doi:10.2337/db12-0230
   PubMed Web of Science ®Google Scholar
• Bühling F, Kunz D, Reinhold D, et al. Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells. Natural Immu. 1994;13:270–279.
   PubMedGoogle Scholar
• Shingu K, Helfritz A, Zielinska-Skowronek M, et al. CD26 expression determines lung metastasis in mutant F344 rats: involvement of NK cell function and soluble CD26. Cancer Immunol Immunother. 2003;52:546–554. doi:10.1007/s00262-003-0392-9
   PubMed Web of Science ®Google Scholar
• Yan S, Marguet D, Dobers J, Reutter W, Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Europ J Immunol. 2003;33:1519–1527. doi:10.1002/eji.200323469
   PubMed Web of Science ®Google Scholar
• Bühling F, Junker U, Reinhold D, Neubert K, Jäger L, Ansorge S. Functional role of CD26 on human B lymphocytes. Immunol Lett. 1995;45:47–51. doi:10.1016/0165-2478(94)00230-O
   PubMed Web of Science ®Google Scholar
• Adams DE, Shao W-H. Epigenetic alterations in immune cells of systemic Lupus erythematosus and therapeutic implications. Cells. 2022;11:506. doi:10.3390/cells11030506
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Hosono O, Mimori T, et al. Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. J Rheumatol. 2002;29:1858–1866.
   PubMed Web of Science ®Google Scholar
• Valizadeh M, Ahmadzadeh A, Behzadi M, Yeganeh F. CD26 mRNA expression in systemic lupus erythematosus. Rheumatol Res. 2018;3:77–82. doi:10.22631/rr.2018.69997.1045
   Google Scholar
• Awadallah MG, Amer GA, Fawzy RM, El-Melouk MS, Egila SS. CD26 mRNA expression level in systemic lupus erythematosus patients attending Benha University Hospital. Egypt J MedMicrobiol. 2020;29(1):55–60. doi:10.21608/ejmm.2020.249857
   Google Scholar
• Seong JM, Yee J, Gwak HS. Dipeptidyl peptidase‐4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: a nationwide population‐based cohort study. Br J Clin Pharmacol. 2019;85:1719–1727. doi:10.1111/bcp.13955
   PubMed Web of Science ®Google Scholar
• Chen Y-C, Chen T-H, Sun -C-C, et al. Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study. Acta Diabetologica. 2020;57:1181–1192. doi:10.1007/s00592-020-01533-5
   PubMed Web of Science ®Google Scholar
• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685–1699. doi:10.1016/S0140-6736(17)30933-9
   PubMed Web of Science ®Google Scholar
• Fiocco U, Rosada M, Cozzi L, et al. Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. Ann Rheumatic Dis. 1993;52:272–277. doi:10.1136/ard.52.4.272
   PubMed Web of Science ®Google Scholar
• Petroff A, Pena Diaz A, Armstrong JJ, Gonga-Cavé BC, Hutnik C, O’Gorman DB. Understanding inflammation-associated ophthalmic pathologies: a novel 3D co-culture model of monocyte-myofibroblast immunomodulation. Ocul Immunol Inflamm. 2021;1–12. doi:10.1080/09273948.2020.1862606
   PubMed Web of Science ®Google Scholar
• Bochaton-Piallat M-L, Gabbiani G, Hinz B. The myofibroblast in wound healing and fibrosis: answered and unanswered questions. F1000Research. 2016;2016:5.
   Google Scholar
• Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Therapy. 2010;12:1–10. doi:10.1186/ar2965
   Web of Science ®Google Scholar
• Ziemek J, Man A, Hinchcliff M, Varga J, Simms RW, Lafyatis R. The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis. Rheumatology. 2016;55:911–917. doi:10.1093/rheumatology/kew003
   PubMed Web of Science ®Google Scholar
• Xin Y, Wang X, Zhu M, et al. Expansion of CD26 positive fibroblast population promotes keloid progression. Exp Cell Res. 2017;356:104–113. doi:10.1016/j.yexcr.2017.04.021
   PubMed Web of Science ®Google Scholar
• Shiobara T, Chibana K, Watanabe T, et al. Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells. Respir Res. 2016;17:1–11. doi:10.1186/s12931-016-0342-7
   PubMed Web of Science ®Google Scholar
• Tabib T, Huang M, Morse N, et al. Myofibroblast transcriptome indicates SFRP2hi fibroblast progenitors in systemic sclerosis skin. Nat Commun. 2021;12:1–13. doi:10.1038/s41467-021-24607-6
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Wu S-T, Liang Y-J, et al. Soluble dipeptidyl peptidase-4 induces fibroblast activation through proteinase-activated receptor-2. Front Pharmacol. 2020;1568. doi:10.3389/fphar.2019.01568
   PubMed Web of Science ®Google Scholar
• Zhang T, Tong X, Zhang S, et al. The roles of dipeptidyl peptidase 4 (DPP4) and DPP4 inhibitors in different lung diseases: new evidence. Front Pharmacol. 2021;3657.
   Web of Science ®Google Scholar
• Abrahami D, Douros A, Yin H, et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ. 2018;2018:360.
   Google Scholar
• Pinto-Lopes P, Afonso J, Pinto-Lopes R, et al. Serum dipeptidyl peptidase 4: a predictor of disease activity and prognosis in inflammatory bowel disease. Inflammat Bow Dis. 2020;26(11):1707–1719. doi:10.1093/ibd/izz319
   PubMed Web of Science ®Google Scholar
• Magro DO, Kotze PG, Martinez CAR, et al. Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn’s disease. Intestinal Res. 2017;15:352. doi:10.5217/ir.2017.15.3.352
   PubMedGoogle Scholar
• Moran G, O’Neill C, Padfield P, McLaughlin J. Dipeptidyl peptidase-4 expression is reduced in Crohn’s disease. Regul Pept. 2012;177:40–45. doi:10.1016/j.regpep.2012.04.006
   PubMedGoogle Scholar
• Di Giovangiulio M, Verheijden S, Bosmans G, Stakenborg N, Boeckxstaens GE, Matteoli G. The neuromodulation of the intestinal immune system and its relevance in inflammatory bowel disease. Front Immunol. 2015;6:590. doi:10.3389/fimmu.2015.00590
   PubMed Web of Science ®Google Scholar
• Detel D, Buljevic S, Pucar LB, Kucic N, Pugel EP, Varljen J. Influence of CD26/dipeptidyl peptidase IV deficiency on immunophenotypic changes during colitis development and resolution. J Physiol Biochem. 2016;72:405–419. doi:10.1007/s13105-016-0491-7
   PubMed Web of Science ®Google Scholar
• Duan L, Rao X, Braunstein Z, Toomey AC, Zhong J. Role of incretin axis in inflammatory bowel disease. Front Immunol. 2017;8:1734. doi:10.3389/fimmu.2017.01734
   PubMed Web of Science ®Google Scholar
• Ning M-M, Yang W-J, Guan W-B, Gu Y-P, Feng Y, Leng Y. Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2. Acta Pharmacol Sin. 2020;41:1446–1456. doi:10.1038/s41401-020-0413-7
   PubMed Web of Science ®Google Scholar
• Mimura S, Ando T, Ishiguro K, et al. Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis. Scand J Gastroenterol. 2013;48:1152–1159. doi:10.3109/00365521.2013.832366
   PubMed Web of Science ®Google Scholar
• Kridin K, Amber K, Khamaisi M, Comaneshter D, Batat E, Cohen AD. Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study. Immunol Res. 2018;66:425–430. doi:10.1007/s12026-018-9005-8
   PubMed Web of Science ®Google Scholar
• Wang T, Yang JY, Buse JB, et al. Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease: real-world evidence in US adults. Diabetes Care. 2019;42:2065–2074. doi:10.2337/dc19-0162
   PubMed Web of Science ®Google Scholar
• Radel JA, Pender DN, Shah SA. Dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease risk: a meta-analysis. Ann. Pharmacother. 2019;53:697–704. doi:10.1177/1060028019827852
   PubMed Web of Science ®Google Scholar
• Malek Abrahimians E, Vander Elst L, Carlier VA, Saint-Remy J-M. Thioreductase-containing epitopes inhibit the development of type 1 diabetes in the NOD mouse model. Front Immunol. 2016;7:67. doi:10.3389/fimmu.2016.00067
   PubMed Web of Science ®Google Scholar
• Iwabuchi A, Kamoda T, Saito M, et al. Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2013;26:1093–1097. doi:10.1515/jpem-2013-0122
   PubMed Web of Science ®Google Scholar
• Varga T, Somogyi A, Barna G, et al. Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes. Pathol Oncol Res. 2011;17:925–930. doi:10.1007/s12253-011-9404-9
   PubMed Web of Science ®Google Scholar
• Osawa S, Kawamori D, Katakami N, et al. Significant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes. Diabetes Res Clin Pract. 2016;113:135–142. doi:10.1016/j.diabres.2015.12.022
   PubMed Web of Science ®Google Scholar
• Ellis S, Moser E, Snell‐Bergeon JK, Rodionova A, Hazenfield R, Garg S. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double‐blind, randomized, crossover trial. Diabetic Med. 2011;28:1176–1181. doi:10.1111/j.1464-5491.2011.03331.x
   PubMed Web of Science ®Google Scholar
• Garg SK, Moser EG, Bode BW, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013;19:19–28. doi:10.4158/EP12100.OR
   PubMed Web of Science ®Google Scholar
• Kumar KH, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract. 2013;100:e55–e58. doi:10.1016/j.diabres.2013.01.020
   PubMed Web of Science ®Google Scholar
• Rahmani-Kukia N, Abbasi A. Physiological and immunological causes of the susceptibility of chronic inflammatory patients to COVID-19 infection: focus on diabetes. Front Endocrinol. 2021;12:84. doi:10.3389/fendo.2021.576412
   Web of Science ®Google Scholar
• Cechin S, Perez-Alvarez I, Fenjves E, et al. Anti-inflammatory properties of exenatide in human pancreatic islets. Cell Transplant. 2012;21:633–648. doi:10.3727/096368911X576027
   PubMed Web of Science ®Google Scholar
• Kim S-J, Nian C, Doudet DJ, McIntosh CH. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes. 2009;58:641–651. doi:10.2337/db08-1101
   PubMed Web of Science ®Google Scholar
• Davanso MR, Caliari-Oliveira C, Couri CEB, et al. DPP-4 inhibition leads to decreased pancreatic inflammatory profile and increased frequency of regulatory T cells in experimental type 1 diabetes. Inflammation. 2019;42:449–462. doi:10.1007/s10753-018-00954-3
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326. doi:10.1056/NEJMoa1307684
   PubMed Web of Science ®Google Scholar
• Ferreira JP, Mehta C, Sharma A, Nissen SE, Rossignol P, Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial. BMC Med. 2020;18(1):1–10. doi:10.1186/s12916-020-01616-8
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242. doi:10.1056/NEJMoa1501352
   PubMed Web of Science ®Google Scholar
• Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care. 2011;34:90–95. doi:10.2337/dc10-1393
   PubMed Web of Science ®Google Scholar
• Gu X, Al Dubayee M, Alshahrani A, et al. Distinctive metabolomics patterns associated with insulin resistance and type 2 diabetes mellitus. Front Mol Biosci. 2020;7:411. doi:10.3389/fmolb.2020.609806
   Web of Science ®Google Scholar
• Tiruppathi C, Miyamoto Y, Ganapathy V, Roesel RA, Whitford GM, Leibach FH. Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains. J Biol Chem. 1990;265:1476–1483. doi:10.1016/S0021-9258(19)40041-0
   PubMed Web of Science ®Google Scholar
• Miyazono K, Heldin C-H. Latent forms of TGF-: molecular structure and mechanisms of activation. Procee Clin Applic. 2008;2008:81–92.
   Google Scholar
• Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 2012;340:248–255. doi:10.1124/jpet.111.186866
   PubMed Web of Science ®Google Scholar
• Mega C, Teixeira de Lemos E, Vala H, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Experim Diab Res. 2011;2011. doi:10.1155/2011/162092
   PubMedGoogle Scholar
• Min HS, Kim JE, Lee MH, et al. Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction. Lab Invest. 2014;94:598–607. doi:10.1038/labinvest.2014.50
   PubMed Web of Science ®Google Scholar
• Matsui T, Nakashima S, Nishino Y, et al. Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis. Lab Invest. 2015;95:525–533. doi:10.1038/labinvest.2015.35
   PubMed Web of Science ®Google Scholar
• Nakashima S, Matsui T, Takeuchi M, Yamagishi S-I. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Hormone Metab Res. 2014;46:717–721. doi:10.1055/s-0034-1371892
   PubMed Web of Science ®Google Scholar
• Salheen S, Panchapakesan U, Pollock C, Woodman O. The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose. Pharmacol Res. 2015;94:26–33. doi:10.1016/j.phrs.2015.02.003
   PubMed Web of Science ®Google Scholar
• Nistala R, Savin V. Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. Am J Physiol Renal Physiol. 2017;312:F661–F670. doi:10.1152/ajprenal.00316.2016
   PubMed Web of Science ®Google Scholar
• Kodera R, Shikata K, Takatsuka T, et al. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochem Biophys Res Commun. 2014;443:828–833. doi:10.1016/j.bbrc.2013.12.049
   PubMed Web of Science ®Google Scholar
• Nabeno M, Akahoshi F, Kishida H, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun. 2013;434:191–196. doi:10.1016/j.bbrc.2013.03.010
   PubMed Web of Science ®Google Scholar
• Makrantonaki E, Jiang D, Hossini AM, et al. Diabetes mellitus and the skin. Rev Endocr Metab Disord. 2016;17:269–282. doi:10.1007/s11154-016-9373-0
   PubMed Web of Science ®Google Scholar
• Röhrborn D, Wronkowitz N, Eckel J. DPP4 in diabetes. Front Immunol. 2015;6:386. doi:10.3389/fimmu.2015.00386
   PubMed Web of Science ®Google Scholar
• Maryam S, Ul Haq I, Yahya G, et al. COVID-19 surveillance in wastewater: an epidemiological tool for the monitoring of SARS-CoV-2. Front Cell Infect Microbiol. 2023;12:1743. doi:10.3389/fcimb.2022.978643
   Web of Science ®Google Scholar
• Elmorsy MA, El-Baz AM, Mohamed NH, Almeer R, Abdel-Daim MM, Yahya G. In silico screening of potent inhibitors against COVID-19 key targets from a library of FDA-approved drugs. Environ Sci Pollut Res Int. 2022;29(8):12336–12346. doi:10.1007/s11356-021-16427-4
   PubMed Web of Science ®Google Scholar
• Yang L, Tu L. Implications of gastrointestinal manifestations of COVID-19. Lancet Gastroent Hepat. 2020;5:629–630. doi:10.1016/S2468-1253(20)30132-1
   PubMed Web of Science ®Google Scholar
• Ul Haq I, Krukiewicz K, Yahya G, et al. The breadth of bacteriophages contributing to the development of the phage-based vaccines for COVID-19: an ideal platform to design the multiplex vaccine. Int J Mol Sci. 2023;24:1536. doi:10.3390/ijms24021536
   PubMed Web of Science ®Google Scholar
• Panther EJ, Lucke-Wold B. Subarachnoid hemorrhage: management considerations for COVID-19. Explorat Neuroprot Thera. 2022;2:65. doi:10.37349/ent.2022.00018
   Google Scholar
• Egbuna C, Chandra S, Awuchi CG, et al. Myth surrounding the FDA disapproval of hydroxychloroquine sulfate and chloroquine phosphate as drugs for coronavirus disease 2019. In: Coronavirus Drug Discovery. Elsevier; 2022:153–168.
   Google Scholar
• Haq IU, Krukiewicz K, Tayyab H, et al. Molecular Understanding of ACE-2 and HLA-conferred differential susceptibility to COVID-19: host-directed insights opening new windows in COVID-19 Therapeutics. J Clin Med. 2023;12:2645. doi:10.3390/jcm12072645
   PubMed Web of Science ®Google Scholar
• Levy E, Delvin E, Marcil V, Spahis S. Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)? Am J Physiol Endocrinol Metab. 2020;319:E689–E708. doi:10.1152/ajpendo.00298.2020
   PubMed Web of Science ®Google Scholar
• Sizemore G, Lucke-Wold B, Small C. Review of SARS-COV-2 systemic impact: building the case for sepsis via virus in the circulatory system. SM J Neurol Disord Strok. 2022;2022:6.
   Google Scholar
• Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. 2020;526:135–140. doi:10.1016/j.bbrc.2020.03.044
   PubMed Web of Science ®Google Scholar
• Meyerholz DK, Lambertz AM, McCray PB. Dipeptidyl peptidase 4 distribution in the human respiratory tract: implications for the Middle East respiratory syndrome. Am J Pathol. 2016;186:78–86. doi:10.1016/j.ajpath.2015.09.014
   PubMed Web of Science ®Google Scholar
• Seys LJ, Widagdo W, Verhamme FM, et al. DPP4, the Middle East respiratory syndrome coronavirus receptor, is upregulated in lungs of smokers and chronic obstructive pulmonary disease patients. Clinl Infect Dis. 2018;66:45–53. doi:10.1093/cid/cix741
   PubMed Web of Science ®Google Scholar
• Widagdo W, Sooksawasdi Na Ayudhya S, Hundie GB, Haagmans BL. Host determinants of MERS-CoV transmission and pathogenesis. Viruses. 2019;11:280. doi:10.3390/v11030280
   PubMed Web of Science ®Google Scholar
• Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circul Res. 2015;116:1491–1504. doi:10.1161/CIRCRESAHA.116.305665
   PubMed Web of Science ®Google Scholar
• Noels H, Bernhagen J. The CXCR4 ligand/receptor family and the DPP4 protease in high-risk cardiovascular patients. Front Immunol. 2016;7:58. doi:10.3389/fimmu.2016.00058
   PubMed Web of Science ®Google Scholar
• Conarello SL, Li Z, Ronan J, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci. 2003;100:6825–6830. doi:10.1073/pnas.0631828100
   PubMed Web of Science ®Google Scholar
• Kulcsar K, Coleman C, Beck S, Frieman M. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight. 2019;4(20):e131774. doi:10.1172/jci.insight.131774
   PubMed Web of Science ®Google Scholar
• Kim KM, Noh JH, Bodogai M, et al. Identification of senescent cell surface targetable protein DPP4. Genes Dev. 2017;31:1529–1534. doi:10.1101/gad.302570.117
   PubMed Web of Science ®Google Scholar
• Atal S, Fatima Z. IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy? Pharm Med. 2020;34:223–231. doi:10.1007/s40290-020-00342-z
   PubMed Web of Science ®Google Scholar
• Zea-Vera A, Cordova EG, Rodriguez S, et al. Parasite antigen in serum predicts the presence of viable brain parasites in patients with apparently calcified cysticercosis only. Clinl Infect Dis. 2013;57:e154–e159. doi:10.1093/cid/cit422
   PubMed Web of Science ®Google Scholar
• Krejner‐Bienias A, Grzela K, Grzela T. Do novel drugs for diabetes help in COVID‐19? Another brick in the wall? J Diab. 2020;12:703. doi:10.1111/1753-0407.13050
   PubMed Web of Science ®Google Scholar
• Inan M, Koyuncu A, Aydin C, Turan M, Gokgoz S, Sen M. Thyroid hormone supplementation in sepsis: an experimental study. Surgery Today. 2003;33:24–29. doi:10.1007/s005950300004
   PubMed Web of Science ®Google Scholar
• Arulmozhiraja S, Matsuo N, Ishitsubo E, Okazaki S, Shimano H, Tokiwa H. Comparative binding analysis of dipeptidyl peptidase IV (DPP-4) with antidiabetic drugs–an ab initio fragment molecular orbital study. PLoS One. 2016;11:e0166275. doi:10.1371/journal.pone.0166275
   PubMed Web of Science ®Google Scholar
• Wilce J, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect. 2020;9:601–604.
   PubMed Web of Science ®Google Scholar
• Bardaweel SK, Hajjo R, Sabbah A. Sitagliptin: a potential drug for the treatment of COVID-19? Acta Pharm. 2021;71:175–184. doi:10.2478/acph-2021-0013
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-1352 19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study 1353 including 8.3 million people. Heart. 2020;106:1503–1511. doi:10.1136/heartjnl-2020-317393
   PubMed Web of Science ®Google Scholar
• van Riet E, Everts B, Retra K, et al. Combined TLR2 and TLR4 ligation in the context of bacterial or helminth extracts in human monocyte derived dendritic cells: molecular correlates for Th1/Th2 polarization. BMC Immunol. 2009;10:1–12. doi:10.1186/1471-2172-10-9
   PubMed Web of Science ®Google Scholar
• Price J, Linder G, Li W, et al. Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study. Clin Exp Immunol. 2013;174:120–128. doi:10.1111/cei.12144
   PubMed Web of Science ®Google Scholar
• Yang W, Cai X, Han X, Ji L. DPP‐4 inhibitors and risk of infections: a meta‐analysis of randomized controlled trials. Diabetes/Metab Res Rev. 2016;32:391–404. doi:10.1002/dmrr.2723
   PubMed Web of Science ®Google Scholar
• Wvan der Zanden R, De Vries F, Lalmohamed A, et al. Use of dipeptidyl-peptidase-4 inhibitors and the risk of pneumonia: a population-based cohort study. PLoS One. 2015;10:e0139367. doi:10.1371/journal.pone.0139367
   PubMed Web of Science ®Google Scholar
• Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‐analysis. Diabetes Obesity Metab. 2012;14:1061–1072. doi:10.1111/j.1463-1326.2012.01610.x
   PubMed Web of Science ®Google Scholar
• Kupferschmidt K. A cheap steroid is the first drug shown to reduce death in COVID-19 patients. Science. 2020;2020:1.
   Google Scholar
• Solerte SB, D’Addio F, Trevisan R, et al. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study. Diabetes Care. 2020;43:2999–3006. doi:10.2337/dc20-1521
   PubMed Web of Science ®Google Scholar
• Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis. 2013;226:305–314. doi:10.1016/j.atherosclerosis.2012.09.012
   PubMed Web of Science ®Google Scholar
• Baz M, Boivin G. Antiviral agents in development for Zika virus infections. Pharmaceuticals. 2019;12:101. doi:10.3390/ph12030101
   Web of Science ®Google Scholar
• Ma J, Zhong M, Xiong Y, et al. Emerging roles of nucleotide metabolism in cancer development: progress and prospect. Aging. 2021;13:13349. doi:10.18632/aging.202962
   PubMedGoogle Scholar
• Ragab D, Laird M, Duffy D, et al. CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients. Cytokine. 2013;63:105–112. doi:10.1016/j.cyto.2013.04.016
   PubMed Web of Science ®Google Scholar
• Rainczuk A, Rao JR, Gathercole JL, et al. Evidence for the antagonistic form of CXC‐motif chemokine CXCL10 in serous epithelial ovarian tumours. Internat J Can. 2014;134:530–541. doi:10.1002/ijc.28393
   PubMed Web of Science ®Google Scholar
• Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109:531–538. doi:10.1007/s00392-020-01626-9
   PubMed Web of Science ®Google Scholar
• Liu Z, Li J, Huang J, et al. Association between diabetes and COVID-19: a retrospective observational study with a large sample of 1880 cases in Leishenshan Hospital, Wuhan. Front Endocrinol. 2020;478. doi:10.3389/fendo.2020.00478
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Asymptomatic and pre-symptomatic COVID-19 in China. Infect Diseases Poverty. 2020;9:1–2. doi:10.1186/s40249-020-00679-2
   PubMed Web of Science ®Google Scholar
• Mauvais-Jarvis F. Aging, male sex, obesity, and metabolic inflammation create the perfect storm for COVID-19. Diabetes. 2020;69:1857–1863. doi:10.2337/dbi19-0023
   PubMed Web of Science ®Google Scholar
• Ghorpade DS, Ozcan L, Zheng Z, et al. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature. 2018;555:673–677. doi:10.1038/nature26138
   PubMed Web of Science ®Google Scholar
• Shekhar S, Copacino CE, Barrera FJ, Hall JE, Hannah-Shmouni F. Insights into the immunopathophysiology of severe COVID-19 in METABOLIC DISOrders. Anna Nat Acad Med Sci. 2020;56:112–115. doi:10.1055/s-0040-1713346
   PubMedGoogle Scholar
• Kirino Y, Sei M, Kawazoe K, Minakuchi K, Sato Y. Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people. Endocr J. 2012;59:949–953. doi:10.1507/endocrj.EJ12-0158
   PubMed Web of Science ®Google Scholar
• Yang F, Zheng T, Gao Y, et al. Increased plasma DPP4 activity is an independent predictor of the onset of metabolic syndrome in Chinese over 4 years: result from the China national diabetes and metabolic disorders study. PLoS One. 2014;9:e92222. doi:10.1371/journal.pone.0092222
   PubMed Web of Science ®Google Scholar
• Cavalu S, Damian G, Dânşoreanu M. EPR study of non-covalent spin labeled serum albumin and hemoglobin. Biophys Chem. 2022;99(2):181–188. doi:10.1016/S0301-4622(02)00182-5
   Google Scholar
• Metwally K, Pratsinis H, Kletsas D, et al. Novel quinazolinone-based 2,4-thiazolidinedione-3-acetic acid derivatives as potent aldose reductase inhibitors. Future Med Chem. 2017;9(18):2147–2166. doi:10.4155/fmc-2017-0149
   PubMed Web of Science ®Google Scholar
• Pang Z, Nakagami H, Osako MK, et al. Therapeutic vaccine against DPP4 improves glucose metabolism in mice. Proc Natl Acad Sci. 2014;111:E1256–E1263. doi:10.1073/pnas.1322009111
   PubMed Web of Science ®Google Scholar
• Fujihara K, Igarashi R, Matsunaga S, et al. Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42). Medicine. 2017;15:96. doi:10.1186/s12916-017-0859-8
   Google Scholar
• Kagal UA, Angadi NB, Matule SM. Effect of dipeptidyl peptidase 4 inhibitors on acute and subacute models of inflammation in male Wistar rats: an experimental study. Int J App Basic Med Res. 2017;7:26. doi:10.4103/2229-516X.198516
   PubMedGoogle Scholar
• Birnbaum Y, Bajaj M, Qian J, Ye Y. Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome. BMJ Open Diabetes Res Care. 2016;4:e000227. doi:10.1136/bmjdrc-2016-000227
   PubMed Web of Science ®Google Scholar
• Beraldo JI, Benetti A, Borges-Júnior FA, et al. Cardioprotection conferred by sitagliptin is associated with reduced cardiac angiotensin II/Angiotensin-(1-7) balance in experimental chronic kidney disease. Int J Mol Sci. 2019;20:1940. doi:10.3390/ijms20081940
   PubMed Web of Science ®Google Scholar
• Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH. The challenge of developing novel pharmacological therapies for non‐alcoholic steatohepatitis. Liver Int. 2010;30:795–808. doi:10.1111/j.1478-3231.2010.02264.x
   PubMed Web of Science ®Google Scholar
• Tacelli M, Celsa C, Magro B, et al. Antidiabetic drugs in NAFLD: the accomplishment of two goals at once? Pharmaceuticals. 2018;11:121. doi:10.3390/ph11040121
   Web of Science ®Google Scholar
• Makdissi A, Ghanim H, Vora M, et al. Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab. 2012;97:3333–3341. doi:10.1210/jc.2012-1544
   PubMed Web of Science ®Google Scholar
• Tang S, Ma W, Bai P. A novel dynamic model describing the spread of the MERS-CoV and the expression of dipeptidyl peptidase 4. Comput Math Methods Med. 2017;2017. doi:10.1155/2017/5285810
   Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. doi:10.1016/S0140-6736(20)30628-0
   PubMed Web of Science ®Google Scholar
• Lagunas‐Rangel FA. Neutrophil‐to‐lymphocyte ratio and lymphocyte‐to‐C‐reactive protein ratio in patients with severe coronavirus disease 2019 (COVID‐19): a meta‐analysis. J med virol. 2020;92:1733–1734. doi:10.1002/jmv.25819
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10:796. doi:10.7150/ijms.6048
   PubMed Web of Science ®Google Scholar